Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression

Rovalpituzumab tesirine (Rova-T) offers a targeted therapy for ~85% of SCLC patients whose tumors express DLL3, but clinical dosing is limited due to off-target toxicities. We hypothesized that a sub-efficacious dose of Rova-T combined with anti-PD1, which alone shows a clinical benefit to ~15% of S...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitorino, Philip, Chuang, Chen-Hua, Iannello, Alexandre, Zhao, Xi, Anderson, Wade, Ferrando, Ronald, Zhang, Zhaomei, Madhavan, Shravanthi, Karsunky, Holger, Saunders, Laura R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569230/
https://www.ncbi.nlm.nih.gov/pubmed/33074129
http://dx.doi.org/10.1016/j.tranon.2020.100883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569230/
https://www.ncbi.nlm.nih.gov/pubmed/33074129
http://dx.doi.org/10.1016/j.tranon.2020.100883

Ejemplares similares